Navigation Links
Government Regulation of Drug Prices will Increase in Both Mature and Emerging Markets, Including Markets that Traditionally Play a Limited Role in Pharmaceutical Pricing

BURLINGTON, Mass., Dec. 8, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the pharmaceutical industry must prepare itself for an increasingly draconian drug pricing environment. While governments in most of the world's developed economies already regulate the prices of most prescription drugs, their control over prices will tighten in the future. According to Decision Resources' new Industry Report, Pharmaceutical Pricing and Reimbursement: Key Facts in Mature and Emerging Markets, even some of the countries that traditionally play a limited role in price setting are poised to introduce stricter controls on pharmaceutical pricing in the future.

The German and United Kingdom governments, which have generally allowed manufacturers relative freedom to set the prices of new drugs, plan to introduce value-based pricing. The United States will continue to allow free pricing of pharmaceuticals, but recently enacted healthcare reform legislation will increase Medicaid rebates and require manufacturers to offer a 50 percent discount on drugs prescribed in the Medicare coverage gap.

"Increased pricing control efforts are not limited to mature markets—governments in emerging markets will also intensify their efforts," said Neil Grubert, M.A., director of pricing and reimbursement research at Decision Resources. "Governments in emerging markets will pay close attention to how proposed prices in their countries compare with prices in other major markets and may demand that manufacturers offer them prices that are lower than those in advanced economies."

The report also finds that substantial budget deficits will force many governments around the world to intensify their efforts to curb spending on healthcare services. Although prescription drugs typically account for only ten to 20 percent of total healthcare expenditures, governments can be expected to focus their cost-containment strategies disproportionately on the pharmaceutical industry.

"Increasingly, payers will limit the most generous reimbursement terms to drugs that have clear evidence of superiority over established therapies. Drugs that lack proof of innovation will be subject to reimbursement restrictions, unless manufacturers offer prices that are in line with, or below, the prices of competing medicines that are already on the market," said Grubert.

About this Industry ReportPharmaceutical Pricing and Reimbursement: Key Facts in Mature and Emerging Markets provides a concise overview of the essential elements of pharmaceutical pricing and reimbursement in 14 markets across the globe. For each of these countries, Decision Resources reviews key factors in market access, including health insurance, pharmaceutical pricing, reimbursement, cost containment, and health technology assessment. In addition, Decision Resources assesses the international outlook and implications for the pharmaceutical industry.

About Decision ResourcesDecision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.Decision ResourcesLisa Osgood781-993-2606 losgood@dresources.comDecision Resources, Inc.Christopher

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. States, Federal Government Could Save $30 Billion by Managing Medicaid Pharmacy More Like Medicare and Commercial Sector Programs
2. InteRNA Technologies Awarded EUR 1.3 Million Innovation Credit From Dutch Government
3. NovaSperse(SM) Nanoparticle Innovator, PharmaNova, Inc., Awarded Four Government Grants Toward Development of New Therapeutic Products Under Congressional Qualifying Therapeutic Discovery Project Initiative
4. Parascript Awarded $244,479.25 Affordable Care Act Grant From the U.S. Government
5. NeoGenomics Awarded $374,000 in R&D Grants from the US Government
6. Spherix Awarded Grant from U.S. Government Under the Patient Protection and Affordable Care Act
7. Cardiogenesis Receives Research Award From Federal Government
8. Local Chinese Government Authorities Approve Pricing and Reimbursement for NeoStems Licensed Adult Stem Cell Treatments for Orthopedic Applications in China
9. Unilife Secures U.S. Government Financial Backing for the Completion of New Global Headquarters and Manufacturing Facility in York, PA
10. Federal Government Selects Thomson Reuters to Build Tool That Streamlines Comparative Effectiveness Research
11. Medical Technology, Funding & Government Experts Address Business, Investment, Reimbursement, Compliance, Innovation, Regulatory and Legal Issues at AdvaMed 2010
Post Your Comments:
(Date:10/12/2015)... 2015 Given the intricacy of the ... to deliver an ophthalmic drug effectively to a specific ocular ... ocular drug delivery. These include dilution of a drug by ... conjunctiva and drug permeation issues with respect to the cornea, ... eye drops, is lost due to the aforementioned barriers. ...
(Date:10/12/2015)... N.J. , Oct. 12, 2015  Shareholder rights ... a securities fraud class action complaint was filed in ... Jersey.  The complaint alleges that officers and directors of ... Act of 1934 between September 15, 2015 and October ... about Amicus Therapeutics, business prospects.  Amicus is a biopharmaceutical ...
(Date:10/12/2015)... 12, 2015  Millions of smokers worldwide have used ... of tobacco. An April 2015 study released ... showed electronic cigarettes to be up to 95 percent ... a decade after the technology was first introduced the ... --> --> Palm ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 2015 , ... Tempe Dental Care, a leading Tempe dentists’ office, celebrates offering ... dentistry for more than 5 years. A leading cause of emergency room visits, ... treatment is not timely. , Sedation dentistry provides an anxiety-free dental ...
(Date:10/13/2015)... ... ... According to an ESPN report published on October 1, Chicago ... him in the left eye during the first day of practice for the season ... of setbacks, including a knee injury that has interfered with his ability to stay ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... developed valuable new strategies for enrolling and serving insurance consumers who do not ... health insurance and pay monthly premiums. In “Health Plan Engagement Strategies: The ABCs ...
(Date:10/13/2015)... ... October 13, 2015 , ... Just under three months ... eMarketing Concepts began a $1 promotion – effectively offering all of their services for ... within weeks the company was flooded with phone calls from interested buyers. As a ...
(Date:10/13/2015)... ... , ... The Bill Howe Family of Companies is an award winning HVAC ... remediation services. Family-owned and operated for 35 years, they have maintained value, ethics and ... two years in a row from the Union Tribune Reader’s Poll, a Healthiest Company ...
Breaking Medicine News(10 mins):